Overview

Neo-NTP-CRT for Locally Advanced ESCC

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that nivolumab combined with neoadjuvant chemoradiotherapy (CRT) is safe and effective in patients with locally advanced esophageal squamous cell carcinoma (LAESCC).

Phase:

Phase 2

Details

Lead Sponsor:

National Taiwan University Hospital

Treatments:

Cisplatin
Nivolumab
Paclitaxel